Trial NCT04227275

View at ClinicalTrials.gov 
Org. Study IDs: CART-PSMA-TGFβRDN-02

Last trial update was posted on 2023-08-21

MeSH Interventions

Cyclophosphamide Fludarabine Interleukin 1 Receptor Antagonist Protein

MeSH Conditions

Prostatic Neoplasms

Other Conditions

Metastatic Castration-resistant Prostate Cancer

Stopping Reasons

Based on the safety events and evidence of biologic activity without sustained clinical responses the Sponsor finds the risk/benefit analysis unfavorable for patients and has terminated the study.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID